• Legend Biotech Corporation recently reported its second-quarter 2026 results, with revenue rising to US$387.5 million from US$255.1 million and net income turning to US$33.2 million from a net loss of US$125.4 million a year earlier.
• Over the first half of 2026, revenue increased to US$692.6 million while the company sharply reduced its net loss to US$21.1 million, highlighting a rapid improvement in profitability metrics.
• With Legend Biotech’s latest quarter showing a shift to profitability, we’ll explore how this earnings progress may influence its investment narrative.

Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

Legend Biotech Investment Narrative Recap

To own Legend Biotech, you need to believe its CAR-T platform, led by CARVYKTI, can support a shift from heavy losses toward more sustainable profitability, while pipeline assets broaden the revenue base over time. The latest quarter’s move to a US$33.2 million net profit supports the near term catalyst of improved earnings visibility, but it does not remove the central risk of dependence on a single commercial product and on its partnership structure.

The most relevant recent development alongside these results is the leadership change, with CARVYKTI unit head Alan Bash stepping in as interim CEO in late July 2026. For a business still reliant on CARVYKTI and its alliance with Janssen, investors will likely watch how this management transition affects execution on manufacturing expansion, commercialization, and progression of early stage programs like LB2501 and LB2102 from here.

Yet against this improving earnings picture, investors should also be aware that...

Legend Biotech's narrative projects $2.2 billion revenue and $464.7 million earnings by 2029.

Uncover how Legend Biotech's forecasts yield a $49.25 fair value, a 135% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$2.7 billion of revenue and US$921.8 million of earnings by 2029, so this profitability step may either reinforce or challenge those expectations depending on how you weigh CARVYKTI concentration risk versus the in vivo lymphoma program that could, in their view, drive a very different outcome.

Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth just $27.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Legend Biotech research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.